What is the appropriate treatment for cellulitis of the nose in an adult without drug allergies or MRSA risk factors?

Treatment for Cellulitis of the Nose

For nasal cellulitis in an adult without MRSA risk factors, start with oral antibiotics targeting β-hemolytic streptococci (such as cephalexin, amoxicillin, or penicillin) for 5-6 days, with mandatory antibiotic coverage given the facial location which is considered an area difficult to drain. 1

Why the Nose Requires Antibiotic Treatment

The nose is specifically identified as a high-risk anatomical location that mandates antibiotic therapy even for simple infections. The IDSA guidelines explicitly state that abscesses in areas difficult to drain—including the face—require antibiotic therapy regardless of whether drainage is performed 1. This is critical because:

• Facial infections carry risk of complications including cavernous sinus thrombosis
• The anatomical complexity limits effective drainage
• Proximity to critical structures demands aggressive treatment

Determining Purulent vs. Nonpurulent Presentation

Your antibiotic choice depends on whether the cellulitis is purulent or nonpurulent:

Nonpurulent cellulitis (no purulent drainage, no drainable abscess):

• First-line: β-lactam antibiotics targeting streptococci
• Options: Cephalexin, amoxicillin, or penicillin
• Duration: 5-6 days 2
• This covers the most common pathogens (β-hemolytic streptococci and methicillin-sensitive S. aureus) 3, 4, 5

Purulent cellulitis (purulent drainage or exudate without drainable abscess):

• Empirical MRSA coverage is required pending cultures
• Options include:
  • Clindamycin alone (covers both streptococci and MRSA) 1
  • TMP-SMX or doxycycline PLUS a β-lactam like amoxicillin 1
  • Linezolid alone 1

Treatment Duration

5-6 days is sufficient for uncomplicated cases 2, 3. The 2021 American College of Physicians guidelines specifically recommend 5-6 days for nonpurulent cellulitis 2, which represents the most recent high-quality guidance. Extend treatment only if the infection has not improved within this timeframe 3.

When to Add MRSA Coverage

Add empirical MRSA coverage if the patient has:

• Purulent drainage
• Penetrating trauma to the nose
• Known MRSA colonization
• Injection drug use
• Signs of systemic toxicity (fever, hypotension, tachycardia)
• Failure to respond to β-lactam therapy after 48-72 hours 1, 3

Without these risk factors, MRSA coverage is unnecessary and contributes to antibiotic overuse 4, 5.

Critical Pitfalls to Avoid

1. Don't skip antibiotics for facial cellulitis: Unlike simple abscesses elsewhere that may only need drainage, facial location mandates antibiotic therapy 1

2. Don't empirically cover MRSA without risk factors: This is a common error that drives resistance. Nonpurulent cellulitis in low-risk patients should receive β-lactam therapy only 3, 4

3. Don't treat for 10-14 days reflexively: Older practice patterns used longer courses, but current evidence supports 5-6 days for uncomplicated cases 2

4. Don't use TMP-SMX alone: It lacks adequate streptococcal coverage. If using TMP-SMX for MRSA coverage, combine it with a β-lactam 1

When to Hospitalize

Consider admission for:

• Signs of systemic illness (SIRS criteria)
• Concern for deeper infection or necrotizing fasciitis
• Immunocompromised state
• Inability to take oral medications
• Poor adherence anticipated 3

Adjunctive Measures

While antibiotics are the cornerstone, address predisposing factors:

• Treat any nasal vestibulitis or fissuring
• Manage underlying skin conditions
• Ensure good hygiene practices 1, 3